Aligos Therapeutics Return on Equity

Aligos Therapeutics (ALGS) currently reports a ROE of -238.24%. That is below the Healthcare sector average of 22.76%. Use the charts on this page to explore Aligos Therapeutics's ROE history and peer comparisons.

Aligos Therapeutics's ROE of -238.24% is lower than the Healthcare sector average of 22.76%. That is roughly 1146.6% below the sector mean. A reading lower peers can reflect different growth expectations, capital structure, or profitability — so it is worth checking the peer comparison chart before drawing conclusions.

There is no universal 'good' ROE, but Aligos Therapeutics's current -238.24% should be judged against Healthcare norms (sector average: 22.76%) and against ALGS's own history. Strong, stable readings often indicate durable competitive advantage; volatile or declining ones deserve a closer look at margins and capital efficiency.

Start with the current ROE of -238.24%, then check the historical chart for trend and the peer comparison chart for relative positioning. The Healthcare average is 22.76%. From there, open related valuation or income-statement pages for Aligos Therapeutics, and consider following ALGS for alerts when major investors trade the stock.

Aligos Therapeutics is classified in the Healthcare sector. On ROE, it currently shows -238.24% versus a sector average near 22.76%. Sector peers often share similar capital intensity and growth regimes, so relative rankings inside Healthcare are usually more informative than comparing ALGS with unrelated industries.